Literature DB >> 7555613

Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction.

W W Yew1, C H Chau, P C Wong, J Lee, C F Wong, S W Cheung, C Y Chan, A F Cheng.   

Abstract

Twenty-five patients who had extensive pulmonary tuberculosis and hepatitis induced by antituberculosis drugs were treated with ciprofloxacin together with other relatively non-hepatotoxic drugs, either during the interim phase awaiting recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others. Only 22 patients were assessable. All tolerated ciprofloxacin well during the phase of hepatic dysfunction. All patients improved with these ciprofloxacin-containing regimens, but the optimal dosage, specific efficacy and long-term safety of the drug in such cases require further evaluation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7555613

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  3 in total

1.  Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus.

Authors:  Lei Pan; Zhan-Sheng Jia; Lin Chen; En-Qing Fu; Guang-Yu Li
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

Review 2.  Fluoroquinolones for the treatment of pulmonary tuberculosis.

Authors:  Susanne Moadebi; Curtis K Harder; Mark J Fitzgerald; Kevin R Elwood; Fawziah Marra
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea.

Authors:  Bo Hyoung Kang; Kyung-Wook Jo; Tae Sun Shim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.